News coverage about Therapix Biosciences (NASDAQ:TRPX) has been trending somewhat positive on Thursday, Accern reports. The research group identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Therapix Biosciences earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.89 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Therapix Biosciences (NASDAQ:TRPX) last posted its quarterly earnings data on Thursday, August 10th. The company reported ($0.54) earnings per share for the quarter.
Therapix Biosciences Company Profile
Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include Joint Pharma that develops THX-TS01 for the treatment of Tourette Syndrome (TS); and BrainBright Pharma, which develops THX-ULD01, a drug candidate based on an ultra-low dose of dronabinol for the treatment for mild cognitive impairment.
Receive News & Ratings for Therapix Biosciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Therapix Biosciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.